Abacus Life, Inc. Files 8-K Report
Ticker: ABXL · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1814287
Sentiment: neutral
Topics: financial-reporting, exhibits
TL;DR
Abacus Life filed an 8-K, mostly financial exhibits. Nothing major to see here yet.
AI Summary
On June 13, 2024, Abacus Life, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status. No specific material events like acquisitions, executive changes, or significant financial results were detailed in the provided excerpt.
Why It Matters
This filing serves as a public record of Abacus Life, Inc.'s financial disclosures, providing transparency to investors and stakeholders regarding the company's financial health and reporting.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate or significant risks.
Key Players & Entities
- Abacus Life, Inc. (company) — Registrant
- June 13, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 001-39403 (identifier) — Commission File Number
- 85-1210472 (identifier) — IRS Employer Identification Number
- 2101 Park Center Drive, Suite 200 Orlando , Florida 32835 (address) — Principal executive offices
- ( 800 ) 561-4148 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Abacus Life, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
When was this 8-K report filed by Abacus Life, Inc.?
The report was filed on June 13, 2024, which is also the date of the earliest event reported.
In which state is Abacus Life, Inc. incorporated?
Abacus Life, Inc. is incorporated in Delaware.
What is the principal executive office address for Abacus Life, Inc.?
The principal executive office address is 2101 Park Center Drive, Suite 200, Orlando, Florida 32835.
Does this filing indicate any specific material events or changes for Abacus Life, Inc.?
Based on the provided excerpt, the filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits,' suggesting routine financial reporting rather than specific material events.
Filing Stats: 757 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2024-06-13 16:21:28
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share ABL The NASDAQ Stock Market L
- $11.50 — of common stock at an exercise price of $11.50 per share ABLLW The NASDAQ Stock Market
Filing Documents
- abl-20240613.htm (8-K) — 30KB
- exhibit991-8xklaunch.htm (EX-99.1) — 13KB
- exhibit991.jpg (GRAPHIC) — 62KB
- 0001628280-24-028060.txt ( ) — 304KB
- abl-20240613.xsd (EX-101.SCH) — 3KB
- abl-20240613_def.xml (EX-101.DEF) — 16KB
- abl-20240613_lab.xml (EX-101.LAB) — 28KB
- abl-20240613_pre.xml (EX-101.PRE) — 17KB
- abl-20240613_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On June 13, 2024, Abacus Life, Inc. (the "Company" or "Abacus") issued a press release announcing the commencement of an underwritten offering of 10,000,000 shares of its common stock, par value $0.0001 per share (the "Common Stock"), made pursuant to the Company's Registration Statement on Form S-1, which was filed with the U.S. Securities and Exchange Commission (the "SEC") but has not yet become effective (such offering, the "Offering"). A copy of the press release announcing the commencement of the Offering is furnished as Exhibit 99.1 hereto.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release entitled "Abacus Life Announces Proposed Public Offering of Common Stock," dated June 13, 2024.
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Abacus' anticipated public offering. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, such as the intended offering terms, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Abacus' most recent annual report on Form 10-K, as amended, and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Abacus' other filings with the SEC, including those contained in the preliminary prospectus and accompanying prospectus related to the public offering to be filed with the SEC. Any forward-looking statements represent Abacus' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Abacus explicitly disclaims any obligation to update any forward-looking statements, except as required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABACUS LIFE, INC. Date: June 13, 2024 By: /s/ Jay Jackson Jay Jackson Chief Executive Officer